Online inquiry

IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1516MR)

This product GTTS-WQ1516MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1516MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1636MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ7505MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ897MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ10736MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ430MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ3289MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ8876MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ7596MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW